for your hiv-1 patients

Proven to suppress. Proven for the road ahead. Proven to suppress. Proven for the road ahead.

SUSTAINED HIGH RATES OF VIROLOGIC
SUPPRESSION THROUGH 144 WEEKS1

  • Study 114 results (snapshot analysis): 72% of
    patients (n=344) in the EVOTAZ arm achieved virologic suppression with
    HIV-1 RNA <50 copies/mL vs 74% in the
    REYATAZ®/ritonavir (r) (n=348) arm at Week 144.1 Study Design
  • EVOTAZ is one pill, once daily taken with food as part of an HIV-1 regimen in adults